The China Food and Drug Administration granted approval to Sihuan Pharmaceutical Holdings Group Ltd. for phase 1, 2 and 3 clinical trials of Fadanafil, a drug for benign prostatic hyperplasia-induced lower urinary tract symptoms and erectile dysfunction.

The drug is being developed by Shandong XuanZhu Pharma Co. Ltd., a unit of Sihuan Pharmaceutical.